Recent advances on dual inhibitors targeting HIV reverse transcriptase associated polymerase and ribonuclease H

Eur J Med Chem. 2023 Mar 15:250:115196. doi: 10.1016/j.ejmech.2023.115196. Epub 2023 Feb 9.

Abstract

Reverse transcriptase (RT) plays an indispensable role in the replication of human immunodeficiency virus (HIV) through its associated polymerase and ribonuclease H (RNase H) activities during the viral RNA genome transformation into proviral DNA. Due to the fact that HIV is a highly mutagenic virus and easily resistant to single-target RT inhibitors, dual inhibitors targeting HIV RT associated polymerase and RNase H have been developed. These dual inhibitors have the advantages of increasing efficacy, reducing drug resistance, drug-drug interactions, and cytotoxicity, as well as improving patient compliance. In this review, we summarize recent advances in polymerase/RNase H dual inhibitors focusing on drug design strategies, and structure-activity relationships and share new insights into developing anti-HIV drugs.

Keywords: Designed multiple ligands; Dual inhibitors; Polymerase; Reverse transcriptase; Ribonuclease H.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents* / pharmacology
  • HIV Reverse Transcriptase*
  • Humans
  • Reverse Transcriptase Inhibitors / pharmacology
  • Ribonuclease H
  • Structure-Activity Relationship

Substances

  • HIV Reverse Transcriptase
  • Ribonuclease H
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents